.svg){kind=small}
Due to web security any ideas and or information sent to RP via this Web site will be deemed not to be confidential and by sending information, you are granting RP unrestricted and irrevocable licence to use, reproduce, display, perform, modify, transmit and distribute. However RP will not release your name or otherwise publicise the fact that information was sent unless RP obtains your permission to do so or if RP is required to do so by law.
Please note that RP does not endorse any other Web sites accessed via this site or accepts any responsibility for the content or accuracy of information contained on that site. In no event will RP be liable to any party for any damages arising from any use of or access to this Web site.
Disclaimer
This Web site has been created solely for the purpose of providing information about services available from Richmond Pharmacology (RP). The site has been compiled in good faith from information available at the time and is therefore subject to change at any time and without notification.
-min.jpg)
.jpg)
Latest news
Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease
June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read moreA first of a kind trial in the fight against malaria
June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read moreEvents
AHA Hypertension Scientific Sessions 2024
5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event
